HK Stock Market Move | SKB BIO (06990) rose over 4% in the morning as its new dual-load ADC drug SKB565 received approval for clinical trial application.
Columbia Biotechnology (06990) rose over 4% before noon. As of this report, it has increased by 3.8%, trading at HKD 510.5, with a trading volume of HKD 95.924 million.
SKB BIO (06990) surged over 4% in the morning session and, as of the time of writing, is up 3.8%, trading at HK$510.5, with a transaction volume of HK$95.924 million.
On the news front, SKB BIO recently announced that the company has received the clinical trial notification from the Center for Drug Evaluation of the National Medical Products Administration, approving its new drug application for the clinical trial of the novel dual-load ADC drug SKB565, intended for the treatment of advanced solid tumors. This is the company's first "dual-load" antibody-drug conjugate to enter the clinical stage, and the approval of SKB565 marks a significant step forward in the company's integrated development strategy of "ADC+IO."
Related Articles
In the first half of the year, Swire Properties reported a profit attributable to shareholders of HK$7.843 billion, an increase of 43% year-on-year.
Etsy (ETSY.US) exceeded revenue expectations but laid off 12% of its staff; the new CEO said it is "restructuring for growth."
CITIC SEC: Kuaishou (01024) subsidiary Keling's revenue compound annual growth rate may reach 104% over the next five years.
In the first half of the year, Swire Properties reported a profit attributable to shareholders of HK$7.843 billion, an increase of 43% year-on-year.
Etsy (ETSY.US) exceeded revenue expectations but laid off 12% of its staff; the new CEO said it is "restructuring for growth."
CITIC SEC: Kuaishou (01024) subsidiary Keling's revenue compound annual growth rate may reach 104% over the next five years.
RECOMMEND
